Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXCO-100 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| VXC0-100 at Dose level 1 | EXPERIMENTAL | Participants will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 1 on Month 6. |
| VXC0-100 at Dose level 2 | EXPERIMENTAL | Participants will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 2 on Month 6. |
| VXC0-100 at Dose level 3 | EXPERIMENTAL | Participants will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 3 on Month 6. |
| COVID-19 mRNA vaccine | EXPERIMENTAL | Participants will receive a COVID-19 mRNA vaccine on Day 1 and then a boost with the same COVID-19 mRNA vaccine at Day 21. |
| VXCO-100 Group 1 | EXPERIMENTAL | Participants 18-55 years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection |
| VXCO-100 Group 2 | EXPERIMENTAL | Participants 18-55 years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection |
| VXCO-100 Group 3 | EXPERIMENTAL | Participants 18-55 years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection |
| VXCO-100 Group 4 | EXPERIMENTAL | Participants 56+ years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection |
| VXCO-100 Group 5 | EXPERIMENTAL | Participants 56+ years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection |
| VXCO-100 Group 6 | EXPERIMENTAL | Participants 56+ years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection |
| Name | Type | Description |
|---|---|---|
| VXCO-100 | BIOLOGICAL | Sterile suspension for injection |
| COVID-19 mRNA vaccine | BIOLOGICAL | Sterile suspension for injection |
Inclusion Criteria: A participant must meet all the following criteria to be eligible for the study: 1. Adults ages 18 years and older 2. Judged by the investigator to be healthy based on participant-reported medical history, physical examination, vital signs, and laboratory assessment. 3. Able to...
VXCO-100 is an investigational monoclonal antibody developed by Eli Lilly and Company for SARS-CoV. It is being studied as a candidate vaccine against SARS-CoV and SARS-CoV-2. The program is in Phase 1 clinical development, with two completed early-stage trials conducted in healthy adult volunteers.
VXCO-100 is being developed for SARS-CoV, with trial protocols also listing SARS-CoV-2. It is a candidate vaccine intended for use in healthy adults. Both completed Phase 1 studies enrolled healthy volunteers aged 18 years and older, and the program remains investigational rather than approved for any use.
VXCO-100 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the two Phase 1 studies of the candidate vaccine, one run in the United States and one run in the Republic of South Africa.
VXCO-100 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no trials are currently active. The program has not been approved by the FDA or any other regulator, so VXCO-100 remains an investigational candidate vaccine for SARS-CoV and SARS-CoV-2.
VXCO-100 has been studied in two completed Phase 1 trials. NCT05938075 evaluated the SARS-CoV candidate vaccine in 130 adults in the Republic of South Africa. NCT05870839 evaluated it in 121 healthy adults in the United States. Together the trials enrolled 251 participants, both controlled and randomized, with healthy volunteers only.
The two completed Phase 1 trials of VXCO-100 enrolled 251 participants in total. NCT05938075 enrolled 130 adults in the Republic of South Africa, and NCT05870839 enrolled 121 healthy adults in the United States. Both studies were controlled and randomized, enrolled adults 18 years and older, and included both sexes.